Abstract:Background: Angiogenesis plays a key role in growth and metastasis of many tumors and is generally mediated by a variety of growth factors, including vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF). Sulfatinib is a highly selective small molecule dual inhibitor of VEGF receptor (VEGFR) and FGF receptor (FGFR), developed by Hutchison MediPharma. It demonstrated potent in vivo inhibitory effects on a variety of human tumor xenografts. The current study was designed to evaluate safety and tolerability, pharmacokinetics, and preliminary anti-tumor activity of sulfatinib. Methods: Eligible patients with histopathologically confirmed solid tumors that had previously failed standard therapies or for whom no standard therapies were available were to be enrolled in cohorts of escalating sulfatinib doses given orally once or twice daily of 28-day cycles until disease progression or unacceptable toxicity. Modified Fibonacci method was used for dose escalation, followed by an expanded cohort at the maximum tolerated dose (MTD). Results: As of Aug 31, 2011, 28 patients have been enrolled in 8 sulfatinib dose cohorts of 50, 75, 110, 150, 200, 265 and 300mg once daily (QD) and 125mg twice daily (BID), respectively. Patients had a median age of 50 (36–70) yrs, with 46% male, ECOG performance status 0–2, and predominantly heavily pretreated. Patient tumor types included colorectal (9), GIST (5), liver (4), neuroendocrine (4), gastric (1), esophageal (1), duodenal (1), cervical (1), retroperitoneal liposarcoma (1), and solid-pseudopapillary tumor of the pancreas (1). Common adverse events (AEs) included fatigue, vomiting, nausea, diarrhea, hypertension, electrolyte disorder and elevated AST/ALT, mostly grade 1/2. Serious AEs and drug related grade 3 AEs were identified in 2 and 5 patients, respectively. Two dose limiting toxicities including a grade 3 coagulation disorders and a grade 3 upper gastrointestinal bleeding were observed in the 50 mg and 265mg cohort, respectively. No unexpected AE has been identified. MTD has not been reached and the dose escalation is ongoing at 300 mg QD and 125mg BID. Among 24 evaluable patients, 7 (29%) had stable disease, with the duration up to 5 months. Five of 9 (56%) patients at doses of ≥ 200mg had stable disease in comparison with 2/15 (13%) patients at doses of Conclusions: Sulfatinib was well tolerated at doses up to 265 mg QD and demonstrated preliminary evidence of anti-tumor activity. PD marker analysis indicates dual inhibition of VEGFR and FGFR. Preliminary PK data suggests good dose proportionality in exposure without marked drug accumulation over the evaluated doses. Dose escalation is ongoing at 300 mg QD and 125mg BID. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr C198.

Structural Basis and Selectivity of Sulfatinib Binding to FGFR and CSF-1R

Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors

Discovery of 4,6-Pyrimidinediamine Derivatives As Novel Dual EGFR/FGFR Inhibitors Aimed EGFR/FGFR1-positive NSCLC.

Structure-based design of a dual-warhead covalent inhibitor of FGFR4

Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4.

Design, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4

Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors

Abstract C198: Phase I study on safety and pharmacokinetics of sulfatinib, a selective VEGFR/FGFR dual inhibitor, in Chinese patients with advanced solid tumors.

Decoding the Conformational Selective Mechanism of FGFR Isoforms: A Comparative Molecular Dynamics Simulation

Molecular Docking and Molecular Dynamics Simulations Reveal the Clinical Resistance of the Gatekeeper Mutation V564F of FGFR2 Against Infigratinib

Gaining Selectivity in the Back Pocket of Fms-Like Tyrosine Kinase 3: A Case Study

Insight into the design of FGFR4 selective inhibitors in cancer therapy: Prospects and challenges

Structural Optimization of Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors

Structural Basis of Mutant-Selectivity and Drug-Resistance Related to CO-1686.

First-in-human Phase I Study of a Selective VEGFR/FGFR Dual Inhibitor Sulfatinib in Patients with Advanced Solid Tumors.

Structural insights into characterizing binding sites in EGFR kinase mutants

Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1-3, suppresses osteosarcoma proliferation and invasion via dual role in tumor cells and tumor microenvironment

Structure-based drug-development study against fibroblast growth factor receptor 2: molecular docking and Molecular dynamics simulation approaches

Structural insights into drug development strategy targeting EGFR T790M/C797S

Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer

Design, synthesis and biological evaluation of 5-amino-1H-pyrazole-4-carboxamide derivatives as pan-FGFR covalent inhibitors